Preprint2021
Development and Validation of a Novel 3-Gene Prognostic Model for Pancreatic Adenocarcinoma Based on Ferroptosis-Related Genes
- Published
- 21 October 2021
- Citations
- 0
- Type
- Preprint
- License
- cc by
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract cc by
Abstract Background: Molecular markers play an important role in predicting clinical outcomes in pancreatic adenocarcinoma (PAAD) patients. Analysis of the ferroptosis-related genes may provide novel potential targets for the prognosis and treatment of PAAD. Methods: RNA-sequence data of PAAD was downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) public databases. The PAAD samples were clustered by a non-negative matrix factorization (NMF) algorithm. The R software package clusterProfiler was used for functional enrichment analysis. By LASSO regression, we established a multi-gene prognostic model, and the model was validated by qPCR and immunohistochemistry and T3M4 cell line. Results: Three molecular subtypes were identified, and a 3-gene signature model (ALOX5, ALOX12, and CISD1) was constructed. The prognostic model showed good independent prognostic ability in PAAD. In the GSE62452 external validation set, the molecular model also showed good risk prediction. The predictive efficiency of the 3-gene signature-based nomogram was significantly better than that of traditional clinical features. Finally, qPCR and immunohistochemical staining and cell function results suggested that ALOX5 may be an oncogene and ALOX12 and CISD1 may be tumor suppressor genes. Conclusions: We present a novel prognostic molecular model for PAAD based on ferroptosis-related genes, which serves as a potentially effective tool for prognostic differentiation in pancreatic cancer patients.